title: Characterisation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH-SY5Y: comparative stimulation by hallucinogenic drugs.
abstract: Stable transfection of the human neuroblastoma cell line SH-SY5Y with the human 5-hydroxytryptamine2A (5-HT2A) or 5-HT2C receptor cDNA produced cell lines demonstrating ligand affinities that correlated closely with those for the corresponding endogenous receptors in human frontal cortex and choroid plexus, respectively. Stimulation of the recombinant receptors by 5-HT induced phosphoinositide hydrolysis with higher potency but lower efficacy at the 5-HT2C receptor (pEC50 = 7.80 +/- 0.06) compared with the 5-HT2A receptor (pEC50 = 7.30 +/- 0.08). Activation of the 5-HT2A receptor caused a transient fourfold increase in intracellular Ca2+ concentration. Whole-cell recordings of cells clamped at -50 mV demonstrated a small inward current (2 pA) in response to 10 microM 5-HT for both receptors. There were no differences in potency or efficacy of phosphoinositide hydrolysis among four hallucinogenic [d-lysergic acid diethylamide (LSD), 1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane (DOI), 5-methoxy-N,N-dimethyltryptamine, and mescaline] and three nonhallucinogenic drugs (m-chlorophenylpiperazine, quipazine, and ergotamine). Comparison of equipotent doses producing 20% of the maximal response induced by 5-HT revealed selective activation of the 5-HT2A receptor by LSD and to a lesser degree by DOI, mescaline, and ergotamine. Quipazine and 5-methoxy-N,N-dimethyltryptamine were relatively nonselective, whereas m-chlorophenylpiperazine selectively activated the 5-HT2C receptor. It is unlikely therefore that hallucinosis is mediated primarily by activity at the 5-HT2C receptor, whereas activity at the 5-HT2A receptor may represent an important but not unique mechanism associated with hallucinogenic drug action.
authors.affiliation: Oxford University-SmithKline Beecham Centre for Applied Neuropsychobiology, University Department of Clinical Pharmacology, Oxford, England.
authors.forename: R A
authors.initials: RA
authors.lastname: Newton
authors.forename: S L
authors.initials: SL
authors.lastname: Phipps
authors.forename: T P
authors.initials: TP
authors.lastname: Flanigan
authors.forename: N R
authors.initials: NR
authors.lastname: Newberry
authors.forename: J E
authors.initials: JE
authors.lastname: Carey
authors.forename: C
authors.initials: C
authors.lastname: Kumar
authors.forename: B
authors.initials: B
authors.lastname: McDonald
authors.forename: C
authors.initials: C
authors.lastname: Chen
authors.forename: J M
authors.initials: JM
authors.lastname: Elliott
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000662:Amphetamines / Q000494:pharmacology; D000978:Antiparkinson Agents / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002831:Choroid Plexus / Q000737:chemistry; D004594:Electrophysiology; D004873:Ergolines / Q000494:pharmacology; D004878:Ergotamine / Q000494:pharmacology; D005625:Frontal Lobe / Q000737:chemistry; D006213:Hallucinogens / Q000494:pharmacology*; D006801:Humans; D006868:Hydrolysis; D007650:Ketanserin / Q000494:pharmacology; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology; D008635:Mescaline / Q000494:pharmacology; D008732:Methoxydimethyltryptamines / Q000494:pharmacology; D009447:Neuroblastoma; D010716:Phosphatidylinositols / Q000096:biosynthesis / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology; D011814:Quipazine / Q000494:pharmacology; D012333:RNA, Messenger / Q000032:analysis; D044402:Receptor, Serotonin, 5-HT2A; D044405:Receptor, Serotonin, 5-HT2C; D011985:Receptors, Serotonin / Q000737:chemistry* / Q000187:drug effects / Q000235:genetics; D011994:Recombinant Proteins / Q000187:drug effects; D012701:Serotonin / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D014316:Tritium; D014407:Tumor Cells, Cultured / Q000737:chemistry
chemical_list: D000316:Adrenergic alpha-Agonists; D000662:Amphetamines; D000978:Antiparkinson Agents; D004873:Ergolines; D006213:Hallucinogens; D008732:Methoxydimethyltryptamines; D010716:Phosphatidylinositols; D010879:Piperazines; D012333:RNA, Messenger; D044402:Receptor, Serotonin, 5-HT2A; D044405:Receptor, Serotonin, 5-HT2C; D011985:Receptors, Serotonin; D011994:Recombinant Proteins; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; D014316:Tritium; D012701:Serotonin; D011814:Quipazine; D008238:Lysergic Acid Diethylamide; D007650:Ketanserin; C015952:4-iodo-2,5-dimethoxyphenylisopropylamine; D004878:Ergotamine; C015068:1-(3-chlorophenyl)piperazine; D008635:Mescaline; C031649:mesulergine; D002118:Calcium